An increasing number of children with non-malignant diseases can be cured by allogeneic haematopoietic stem cell transplantation (HSCT). Treosulfan (L-treitol-1,4-bis-methanesulfonate) is being used more frequently for conditioning, owing to its' lower toxicity profile compared with conventional myeloablative regimens. A retrospective analysis was performed of children registered in the EBMT database, who received treosulfan before HSCT between January 2005 and 2010, to identify possible doserelated toxicity and determine the incidence of engraftment, treatment-related mortality and overall survival (OS). Results from 316 transplants from 11 different countries are presented. Ninety-five (30%) were under 1 year of age at the time of transplant. OS was 83% and event-free survival was 76%; 3-year OS and event-free survival of infants below 1 year were 79% and 73%, respectively. No association was found with age at transplant, dose of treosulfan given, other agents used in combination with treosulfan, donor type, stem cell source, or second or subsequent transplant. In this report of the largest number of children to date receiving treosulfan for non-malignant diseases, treosulfan is shown to be a safe and effective agent even for those under 1 year of age at the time of transplant. Further prospective studies are needed using precisely defined protocols with pharmacokinetic monitoring and detailed chimerism analysis. In addition, long-term studies will be vital to determine long-term effects, for example, on fertility in comparison with other regimens.
INTRODUCTION
Treosulfan (L-treitol-1,4-bis-methanesulfonate) is the pro-drug of L-epoxybutane, a water-soluble bifunctional alkylating agent, which has been used as an antineoplastic agent for treating ovarian carcinoma in particular for many years. Owing to its' myeloablative and immunosuppressive properties, it has been shown to provide effective haematopoietic stem cell transplant (HSCT) conditioning with reduced risk of toxicities, in particular veno-occlusive disease (VOD), compared with traditional combinations of busulfan and cyclophosphamide. 1, 2 It was first used in an HSCT setting in a group of adult patients with haematologic malignancies considered ineligible for other myeloablative preparative regimens in combination with either cyclophosphamide 3 or fludarabine. 4 Good outcomes with respect to toxicity, achievement of complete donor chimerism, low GvHD rate and low treatment-related mortality and relapse rates were shown. Since then, treosulfan has increasingly been used for paediatric patients undergoing HSCT for both malignant and nonmalignant diseases. [5] [6] [7] [8] [9] [10] [11] [12] An increasing number of patients with non-malignant disorders are eligible for HSCT and these patients present different challenges compared with those with malignant diseases: children with inherited disorders such as SCID often come to transplant as infants under 1 year of age with organ damage and co-morbidities. GvHD, which may be associated with a beneficial GvL effect in patients with high-risk haematological diseases, is of no added value in controlling the underlying genetic illness and may adversely affect subsequent immune reconstitution and have an unnecessarily negative impact on HSCT-related morbidity and quality of life in the short and long term. Concerns about relapse in high-risk malignant diseases do not apply 13 but mixed chimerism in high-risk haemoglobinopathies can be a problem.
14 Treosulfancontaining regimens achieving a high rate of stable donor engraftment in the required lineage, with a reduced regimenrelated toxicity, and low rate of GvHD are therefore attractive. 
PATIENTS AND METHODS
There were 843 patients below the age of 18 years, who underwent HSCT between January 2005 and July 2010 registered in the EBMT database, 1 who were eligible for this retrospective study. The survey was performed in the Autumn of 2011 and the analysis was done at the end of 2012. The study was conducted in accordance with the EBMT Guidelines for retrospective studies. Questionnaires were sent to the respective centres but no toxicity data were received for 211 patients and 6 patients were excluded for whom no treosulfan dose was given. Five hundred and thirty-three allogeneic and 93 autologous transplants from 13 countries were included in the analysis. Three hundred and sixteen transplants in patients with non-malignant diseases from 11 countries (UK, Germany, Italy, The Netherlands, Poland, Czech Republic, Israel, Russia, Austria, Spain and Australia) are presented here. There were no autologous transplants for non-malignant diseases. Patient characteristics according to age at transplant, gender and number of transplants are shown in Table 1 .
Ninety-five (30%) children were under 1 year of age at transplant. The numbers undergoing first, second and third transplants were 290, 23 and 3, respectively.
Diagnoses of the patients were inherited disorders 188 (59%), including 144 with primary immunodeficiencies, 39 metabolic disorders and 5 not specified, haemoglobinopathies 70 (22%), histiocytic disorders 32 (10%), bone marrow failure 24 (8%) and autoimmune disease 2 (1%). Table 2 describes the age groups and the various disease categories.
Donors were matched sibling 69 (22%), matched other related 25 (8%), matched unrelated 39 (12%), mismatched related 29 (9%), mismatched unrelated 16 (5%) and unrelated not defined 138 (44%). Mismatch was defined as anything o9 out of 10 HLA identical. Stem cell sources were the bone marrow 167 (53%), bone marrow+cord progenitors 8 (2.5%), bone marrow+peripheral blood 3 (1%), cord progenitors 50 (15%), peripheral blood 87 (28%) and peripheral blood+cord progenitors 1 (0.5%).
The median total dose of treosulfan was 42 g/m 2 in three divided doses with a range from o3 × 11 to 43 × 15 g/m 2 . Roughly equal numbers of patients received a median total dose of fludarabine 150 mg/ m 2 (106), cyclophosphamide 200 mg/kg (98), or fludarabine+thiotepa median dose 8 mg/kg (104) in addition to treosulfan. Eight patients received fludarabine and melphalan in addition to treosulfan. Choice of additional agents was dependent on the centre preference, as there were no defined protocols for different diseases at the time beyond the inborn errors working party guidelines, which can be found on the EBMT website. Most children received GvHD prophylaxis containing CsA (n = 284, 90%), combined with mycophenolate mofetil in (n = 110, 35%) or methotrexate (n = 101, 32%). Acute and chronic GvHD were graded according to the Seattle criteria. 15 Early regimen-related toxicity until day +100 was defined and graded using the Short Name based on the Common Terminology Criteria for Adverse Events v3.0, available online at: http://ctep.cancer.gov/forms/. The median follow-up time calculated using the reverse Kaplan-Meier estimator, which also takes into account the patients who died, was 2.16 (range 0.02-6.37) years; the median follow-up time of all survivors was 2.08 years (range 0.09-6.37). There were eight survivors with follow-up of o0.5 years.
Statistical methods
The univariate statistical analysis was performed in several prospectively identified subgroups defined by diagnosis, conditioning regimen, number of HSCT and patient age. Kaplan-Meier estimates and log-rank test 16, 17 were used to evaluate overall survival (OS). For OS, deaths from any cause were considered an event. Cumulative incidences of events were calculated by the method of Fine and Gray 18 for censored data subject to competing risks, and compared using the Gray test. 19 The cumulative incidence of neutrophil engraftment was calculated taking into account the competing risks of lost graft, death without engraftment and subsequent HSCT, and the cumulative incidence of transplant-related mortality-taking into account the deaths after graft loss and subsequent HSCT without treosulfan-based conditioning. Mantel-Haenszel χ 2 -test and χ 2 -test were used to compare categorical non-time-to-event variables: toxicities and acute GvHD at day +100 and chronic GvHD at 1 year. Further, a multivariate analysis was performed to study the impact of possible confounding factors on the defined outcomes. Cox regression 11, 12 was used to model the time to transplantrelated mortality and OS. The statistical analysis was done with SAS System V9.2 (2008, SAS Institute, Cary, NC, USA). All P-values below 5% were considered significant.
RESULTS
Age, diagnosis, other conditioning drugs, GvHD prophylaxis and stem-cell source correlated significantly with treosulfan dose. Younger patients were more likely to receive a lower dose. More patients received the higher dose rather than the lower dose for all diagnoses. When thiotepa was added, it was almost always with the higher dose of treosulfan and fludarabine. Abbreviation: N = number.
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Early regimen-related toxicity Early regimen-related toxicity is shown in detail in Table 3 Table 4 describes toxicity in correlation with treosulfan dose, age, diagnosis and number of HSCT.
Gastrointestinal. There was no association between grade 3 or 4 vomiting or diarrhoea with age, dose, diagnosis, first or subsequent transplant, donor type or additional conditioning agents.
Stomatitis was worse when an additional third conditioning agent, that is, thiotepa or melphalan was used (data not shown).
Respiratory. All grades of respiratory toxicity were higher in children below the age of 1 year. There was less respiratory toxicity in the children with haemoglobinopathies than in other diagnoses. For inherited disorders with the highest number of patients under 1 year of age (79), there was no significant difference between those less than or over 6 months of age but just for those less than 1 year compared with over a year of age.
Liver. There was no association between raised bilirubin and age, dose, diagnosis, first or subsequent transplant, donor type, stem cell source or additional conditioning agents.
Aspartate transaminase was more likely to be elevated in those with haemoglobinopathies and histiocytic disorders, and second transplants. There was no statistically significant association between VOD and age, dose, diagnosis, 1st or subsequent transplant, donor type, stem cell source or additional conditioning agents. Only 5% of patients developed VOD grade 1 or 2 and no patients had grade 3 or 4 VOD.
Neurological. Children under 6 months of age were more likely to have CNS toxicity limited to grade 1-2. There was no association between peripheral neurotoxicity and age, dose, diagnosis, first or subsequent transplant, donor type or additional conditioning agents.
GvHD
Thirty eight per cent (121/316) of patients had acute GvHD but only 10% had grade 3 or 4. There was no significant difference in the incidence of acute GvHD grade 3 or 4 between age groups, treosulfan dose, donor type, stem cell source and additional conditioning drugs used. There was a significantly higher incidence of chronic GvHD in histiocytic disorders than in other diseases as shown in the Supplementary Table. Non-engraftment/graft loss Incidence of graft failure was low (n = 16, 5.1%) and no significant associated factors were found. One of four patients who had o3 × 11 g/m 2 failed to engraft having received a cord blood for a metabolic disorder with fludarabine, although six of six, who received o 3 × 9 g/m 2 , engrafted and only one of them had thiotepa in addition to fludarabine, one had treosulfan with cyclophospamide. The majority of mismatched family donor recipients had treosulfan with cyclophosphamide (12) or with fludarabine and thiotepa (11), one of whom had graft loss. One mismatched family donor recipient who had treosulfan with fludarabine and melphalan also had graft loss. Three recipients with fludarabine alone engrafted successfully. Further details are shown in the Supplementary Table. Survival There was no significant difference in OS regarding diagnosis, age at transplant or with dose of treosulfan given (Figures 1, 2, 3) . The very small group of six patients with other combinations of conditioning drugs (these patients received additionally melphalan and fludarabine) for first transplant had significantly worse OS than the other patient subgroups (Figure 4) . Figures for event-free survival are provided as Supplementary Material. The 3-year OS for 59 patients with thalassaemia was 91% with an event-free survival of 77%. The 3-year OS and event-free survival for 11 patients with sickle cell anaemia was 100%.
Data on the cause of death were missing for 5 of 51 deaths. Of the remaining 46, the following were the main causes: Infection (19), interstitial pneumonitis (7), multi-organ failure (6), haemorrhage (6), GvHD (5), graft rejection or poor graft function (3), pulmonary toxicity (3), cardiac toxicity (1) and CNS toxicity (1) .
Using multivariate analysis, we could not identify any significant association of diagnosis, age, dose, number of HSCT donor or stem cell source with outcome (Table 5) .
DISCUSSION
The use of treosulfan for conditioning for HSCT in children with non-malignant disorders is increasing, in particular in patients with inherited disorders and haemoglobinopathies. 5, 6, 9, 14, 20, 21 In this retrospective EBMT study, we evaluated the toxicity profile and outcome of 316 patients with non-malignant diseases undergoing HSCT, following treosulfan-based conditioning. To our knowledge, this is the largest such study to date. The 3-year OS in this cohort was 0.83 (±0.02), which is consistent with other published series. 4, 5, 7, 8, [15] [16] [17] Treosulfan is shown to be a safe and effective Abbreviations: AST = aspartate transaminase; CNS = central nervous system; PN = peripheral neurological; VOD = veno-occlusive disease.
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Bone marrow failure: 3y-pOS=83%, SE=8% (n=24, 4 events)
Immune deficiencies: 3y-pOS=80%, SE=4% (n=144, 26 events) Sickle cell anaemia: 3y-pOS=100%, SE=0% (n=11, 0 events) Thalassaemia: 3y-pOS=91%, SE=4% (n=59, 5 events)
Histiocytic disorders: 3y-pOS=75%, SE=8% (n=32, 9 events) Disorders of metabolism: 3y-pOS=83%, SE=6% (n=39, 6 events) Figure 1 . No significant difference in 3-year OS with diagnosis.
agent for such children, even those under 1 year of age at the time of transplant. Multivariate analysis showed no association of transplant-related mortality with age at transplant, dose of treosulfan given, other agents used in combination with treosulfan, type of donor, stem cell source or even second or subsequent transplant. It is of particular interest that the addition of thiotepa to treosulfan and fludarabine did not increase acute toxicity. This combination, which has gained popularity in matched donor transplantation in haemoglobinopathies, also facilitated the engraftment of mismatched donors in a variety of diseases. The very small group of six patients who received melphalan in addition to treosulfan and fludarabine for first transplant did significantly worse. It is not clear why this occurred as other patients have tolerated this combination quite well.
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Toxicity was not associated with an increasing dose of treosulfan. There was more respiratory toxicity in the patients under 1 year of age, which may be due to the large number of primary immunodeficiencies in this group, who may have had respiratory infections. Pre-existing respiratory impairment in children with SCID is known to be associated with a worse outcome. 22 CNS toxicity, although transient in all cases, was more common in the children under 6 months of age. These very young children are on many other drugs at the time of transplant, in particular calcineurin inhibitors. In addition, viral encephalitis as a consequence of SCID could have an additional role. Treosulfan and its' active monoepoxide have been found at low concentration in the cerebrospinal fluid of rats given treosulfan 23 and it is also possible that in very young babies the blood barrier may be less mature.
There was very little overall toxicity and very little graft loss, and therefore it is difficult to establish the optimal doses for different age groups of children. Our study has the limitations of being a registry-based retrospective study. There is a lack of data available on the use of serotherapy and levels of chimerism achieved. Further prospective studies are needed in non-malignant diseases using precisely defined protocols with pharmacokinetic monitoring and detailed chimerism analysis. 24 This study confirms a low incidence of CNS toxicity and VOD with treosulfan, both of which may give treosulfan an advantage over busulfan; however, there are recent promising results for some busulfan-containing regimens, in particular with carefully targeted low-dose busulfan in combination with fludarabine, which seems to be associated with very limited toxicity. 25 It is therefore essential that studies are performed looking at the long-term effects of these drugs, for example, on fertility, and comparing treosulfan-containing with busulfan-containing regimens. Abbreviations: BM = bone marrow; CB = cord blood; CI = confidence interval; HR = hazard ratio; HSCT = haematopoietic stem cell transplantation; MSD = sibling donor; OS = overall survival; PB = peripheral blood; TRM = related mortality.
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